Virus-Specific Cytotoxic CD4+ T Cells for the Treatment of EBV-Related Tumors
- 15 May 2010
- journal article
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 184 (10) , 5895-5902
Abstract
Although adoptive immunotherapy with CD8+ CTL is providing clinically relevant results against EBV-driven malignancies, the effector role of CD4+ T cells has been poorly investigated. We addressed this issue in a lymphoblastoid cell line-induced mouse model of posttransplant lymphoproliferative disease (PTLD) by comparing the therapeutic efficacy of EBV-specific CD4+ and CD8+ T cell lines upon adoptive transfer. CD4+ T cells disclosed a long-lasting and stronger proliferative potential than CD8+ T cells, had a similar activation and differentiation marker profile, efficiently killed their targets in a MHC class II-restricted manner, and displayed a lytic machinery comparable to that of cognate CD8+ T cells. A detailed analysis of Ag specificity revealed that CD4+ T cells potentially target EBV early lytic cycle proteins. Nonetheless, when assessed for the relative therapeutic impact after in vivo transfer, CD4+ T cells showed a reduced activity compared with the CD8+ CTL counterpart. This feature was apparently due to a strong and selective downmodulation of MHC class II expression on the tumor cells surface, a phenomenon that could be reverted by the demethylating agent 5-aza-2′-deoxycytidine, thus leading to restoration of lymphoblastoid cell line recognition and killing by CD4+ T cells, as well as to a more pronounced therapeutic activity. Conversely, immunohistochemical analysis disclosed that HLA-II expression is fully retained in human PTLD samples. Our data indicate that EBV-specific cytotoxic CD4+ T cells are therapeutic in mice bearing PTLD-like tumors, even in the absence of CD8+ T cells. These findings pave the way to use cultures of pure CD4+ T cells in immunotherapeutic approaches for EBV-related malignancies.Keywords
This publication has 50 references indexed in Scilit:
- Methylation of CIITA promoter IV causes loss of HLA-II inducibility by IFN- in promyelocytic cellsInternational Immunology, 2008
- Tumor-specific Th17-polarized cells eradicate large established melanomaBlood, 2008
- Treatment of Metastatic Melanoma with Autologous CD4+ T Cells against NY-ESO-1New England Journal of Medicine, 2008
- Standardized and Highly Efficient Expansion of Epstein-Barr Virus-Specific CD4 + T Cells by Using Virus-Like ParticlesJournal of Virology, 2008
- The Transcriptome of Human Cytotoxic T Cells: Similarities and Disparities Among Allostimulated CD4+ CTL, CD8+ CTL and NK cellsAmerican Journal of Transplantation, 2008
- Immunodominance of Lytic Cycle Antigens in Epstein-Barr Virus-Specific CD4+ T Cell Preparations for TherapyPLOS ONE, 2007
- Primary CD4+T-Cell Responses Provide both Helper and Cytotoxic Functions during Epstein-Barr Virus Infection and Transformation of Fetal Cord Blood B CellsJournal of Virology, 2007
- Distinct memory CD4+ T-cell subsets mediate immune recognition of Epstein Barr virus nuclear antigen 1 in healthy virus carriersBlood, 2006
- Adoptive immunotherapy for cancer: building on successNature Reviews Immunology, 2006
- Epstein-Barr Virus Nuclear Antigen 1Journal of Experimental Medicine, 2004